Geautomatiseerde glucosecontrole thuis voor mensen met chronische ziekten (CLOSE 2019)

CLOSE enhances the use of an artificial pancreas (AP), an innovation that assists severely ill people with type 2 diabetes. By providing strong digital connections to medical professionals, new analytical tools and training, CLOSE supports chronic patients in living at home, and promises patients and their families a better quality of life.The artificial pancreas (AP) approaches a “technical cure” of diabetes as it measures glucose levels and uses an algorithm to determine the right amount of insulin to infuse in the patient. CLOSE seeks to improve the chronic care made possible by the AP. Conceived during the set-up of EIT Health, CLOSE employs decades of expertise in global diabetes markets and closed-loop technology, combined with a patient-centered attitude, to inform the co-creative process.

CLOSE seeks to improve care and quality of life for patients with type 2 diabetes by enhancing the AP with related product and service packages to create AP+. By adding training (train-the-trainer), telemedical consultation and tools for outcome prediction and performance measurement to the AP, CLOSE will increase effectiveness of the AP, as well as eligibility for reimbursement.

During the EIT Health-funded phase of its development, CLOSE starts by establishing an AP+ paradigm to improve the efficacy of a French AP homecare ecosystem. CLOSE will build on lessons learned during this process to scale up the AP+ system, increasing the geographical reach, audiences, functionalities and interconnectedness.

Following the EIT Health-funded project phase, an AP+ business and development partnership emerging from CLOSE will grow a portfolio of highly adaptable AP+ solutions, which recognise the diversity of diabetes, people and care environments. The ambition is to improve care for patients, alleviate strain on their families, prevent further health complications, and reduce treatment costs.